NASDAQ:ORGS Orgenesis (ORGS) Stock Price, News & Analysis $0.58 0.00 (0.00%) As of 09/23/2026 09:40 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC Filings About Orgenesis Stock (NASDAQ:ORGS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Orgenesis alerts:Sign Up Key Stats Today's Range$0.58▼$0.5850-Day Range$0.00▼$0.7152-Week Range$0.00▼$1.00Volume100 shsAverage Volume949 shsMarket Capitalization$3.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Orgenesis Inc. is a biotechnology company focused on developing and commercializing advanced cell and gene therapies. Its work centers on autologous cell therapies, which use a patient’s own cells, and on technologies intended to support the processing and manufacture of these therapies closer to the point of care. The company’s platform includes its POCare ecosystem, which is designed to combine cell-therapy development, manufacturing, clinical applications and related data-management capabilities. Orgenesis has also developed Mobile Processing Units, or MPUs, intended to provide localized, controlled environments for producing certain cell-based therapies and potentially improve access to personalized treatments. Orgenesis has pursued collaborations with academic institutions, healthcare organizations and biotechnology partners in support of its therapeutic programs and decentralized manufacturing model. The company has operated internationally, with activities associated with the United States, Israel and Europe. Orgenesis has been led by Vered Caplan, who has served as chief executive officer and has been closely associated with the company’s cell-therapy and POCare strategy.AI Generated. May Contain Errors. Read More Receive ORGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORGS Stock News HeadlinesOrgenesis Shareholders Approve Major Charter and Stock IncreaseJune 4, 2026 | theglobeandmail.comOrgenesis Issues Alpha Warrant in New Financing DealJanuary 26, 2026 | tipranks.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 24 at 1:00 AM | Porter & Company (Ad)Orgenesis Subsidiary Secures Convertible Loan AgreementSeptember 16, 2025 | tipranks.comOrgenesis Director Ashish Nanda ResignsAugust 25, 2025 | tipranks.comOrgenesis Faces Multiple Leadership Resignations in AugustAugust 20, 2025 | msn.comOrgenesis Delays Filing of Quarterly ReportMay 16, 2025 | tipranks.comOrgenesis Delays 10-K Filing Amid Financial ChallengesApril 1, 2025 | tipranks.comSee More Headlines ORGS Stock Analysis - Frequently Asked Questions How have ORGS shares performed this year? Orgenesis' stock was trading at $0.15 at the beginning of 2026. Since then, ORGS stock has increased by 286.7% and is now trading at $0.58. How were Orgenesis' earnings last quarter? Orgenesis Inc. (NASDAQ:ORGS) announced its quarterly earnings results on Friday, August, 11th. The company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.60 by $2.10. The firm had revenue of $6.98 million for the quarter. When did Orgenesis' stock split? Orgenesis's stock reverse split on Wednesday, September 25th 2024.The 1-10 reverse split was announced on Monday, September 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Does Orgenesis have any subsidiaries? Orgenesis subsidiaries include these companies: Koligo Therapeutics, and Tamir Biotechnology Inc. How do I buy shares of Orgenesis? Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Orgenesis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Orgenesis investors own include NVIDIA (NVDA), Energy Transfer (ET), BioLineRx (BLRX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and Enbridge (ENB). Company Calendar Last Earnings8/11/2023Today9/24/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ORGS CIK1460602 Webwww.orgenesis.com Phone(480) 659-6404FaxN/AEmployees150Year Founded2008Profitability EPS (Trailing Twelve Months)($11.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.36 million Net Margins-3,827.81% Pretax Margin-3,931.93% Return on EquityN/A Return on Assets-130.18% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$662 thousand Price / Sales4.53 Cash FlowN/A Price / Cash FlowN/A Book Value($6.58) per share Price / Book-0.09Miscellaneous Outstanding Shares5,169,000Free Float4,527,000Market Cap$3.00 million OptionableNo Data Beta3.16 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ORGS) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersEveryone remembers January's silver spike. Then what?Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...i2i Marketing Group, LLC | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | SponsoredCongress Passes Landmark Digital Asset Law Wall Street Is WatchingThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORGS Stock Alerts